Low Dose Naltrexone and Methylene Blue: A Clinician's Framework for Precision Dosing, Neuroimmune Modulation, and Mitochondrial Support in Complex Chronic Illness

Clinical Education Series  |  Integrative Pharmacology

Low Dose Naltrexone and Methylene Blue:

A Clinician's Framework for Precision Dosing, Neuroimmune Modulation, and Mitochondrial Support in Complex Chronic Illness

Yoon Hang "John" Kim, MD, MPH  |  Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician  |  www.directintegrativecare.com

Published: March 2026  |  Peer-Reviewed References Included

Introduction

The treatment of complex chronic illness has entered a period of necessary recalibration. Decades of experience with immunomodulatory and neuroendocrine agents have taught integrative clinicians that two variables — mechanism and dose — are inseparable. Nowhere is this more apparent than in the clinical pharmacology of low dose naltrexone (LDN) and methylene blue (MB). These two agents, once considered peripheral curiosities in mainstream medicine, are now attracting rigorous scientific attention as complementary tools for addressing the intertwined domains of neuroimmune dysregulation and mitochondrial dysfunction that define a growing class of patients with treatment-resistant chronic conditions.

The purpose of this clinical education article is to synthesize the available mechanistic and clinical evidence for LDN and MB, with particular emphasis on precision dosing, paradoxical reactions, post-COVID physiological shifts, and the emerging logic of their combined application. This is not a systematic review; it is a practitioner-oriented framework grounded in published evidence and refined by clinical observation.

Part I: Low Dose Naltrexone — Rethinking the Therapeutic Window

The Paradigm Shift: Why Dose Defines the Drug

Naltrexone was developed in 1963 as a competitive opioid receptor antagonist prescribed at doses of 50 to 150 mg per day for the treatment of opioid and alcohol use disorders. At these conventional doses, naltrexone produces sustained, near-complete blockade of mu-, delta-, and kappa-opioid receptors, effectively preventing exogenous opioids from binding. This is a pharmacologically blunt intervention: comprehensive, dose-proportional, and entirely antagonistic.

Low dose naltrexone operates within a fundamentally different pharmacological register. At doses ranging from 1.5 to 4.5 mg — and, increasingly, at microgram or even nanogram quantities — the duration of opioid receptor occupancy is brief and transient rather than sustained. This distinction is not merely quantitative; it is qualitatively transformative. The biological consequences of transient versus sustained receptor blockade diverge so substantially that the compound appears to become, in essence, a different drug at different doses. The phenomenon of hormesis — where a compound exerts low-dose stimulatory effects and high-dose inhibitory effects — provides a theoretical framework for understanding this dose-dependent duality.

Historically, LDN has been initiated at 1.5 mg and titrated upward toward 4.5 mg. This range, while therapeutically valid for many patients, is increasingly recognized as excessive for a significant subset of the contemporary patient population. Clinicians with extensive LDN experience now frequently employ starting doses of 0.5 mg or lower, with some patients — particularly those with Long COVID, fibromyalgia, or mast cell activation syndrome (MCAS) — requiring titration through microgram quantities before tolerating even a fraction of a milligram. The teaching imperative here is clear: the right dose is not the dose found in the original literature, nor the dose most easily prescribed. It is the dose that each individual patient can tolerate without paradoxical harm.

Poliwoda S, Noss B, Truong GTD, et al. The Utilization of Low Dose Naltrexone for Chronic Pain. CNS Drugs. 2023;37(8):663-670. PMID: 37505425.

Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-9. PMC3962576.

The Endorphin Biology Underlying LDN Mechanism

The most widely cited explanation for LDN's therapeutic effects involves what is termed the opioid rebound phenomenon. When naltrexone is administered at low doses, it transiently occupies opioid receptors for a period corresponding to its short half-life. The body interprets this transient receptor blockade as a relative deficit in endogenous opioid signaling, and responds by upregulating both opioid receptor density and the production of endogenous opioids, including beta-endorphins and enkephalins. When LDN is subsequently cleared and the receptors become available again, these newly synthesized endogenous opioids bind with enhanced efficiency, producing downstream analgesic, mood-stabilizing, and immunomodulatory effects. This is the theoretical basis for the clinical practice of nighttime dosing: LDN is taken in the evening so that the rebound surge in endorphins coincides with natural endogenous opioid production rhythms in the early morning hours.

It is important to acknowledge a significant nuance in the scientific literature. A 2021 study published in eNeuro examined whether LDN altered the activity of proopiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus — a primary source of beta-endorphin — and found no evidence of altered opioid receptor sensitivity or systemic beta-endorphin concentrations following LDN treatment. This finding challenges the classical opioid rebound model and suggests that LDN's benefits may be partially independent of this mechanism, at least as mediated through hypothalamic POMC neurons.

A second, highly compelling mechanism involves LDN's antagonism of Toll-like receptor 4 (TLR4) on microglial cells in the central nervous system. Microglial TLR4 activation drives neuroinflammation through production of pro-inflammatory cytokines, nitric oxide, and excitatory amino acids. LDN's blockade of TLR4 dampens this neuroinflammatory cascade, reducing central sensitization and likely explaining its efficacy across conditions as varied as fibromyalgia, multiple sclerosis, Crohn's disease, and complex regional pain syndrome. The two mechanisms — opioid rebound and TLR4 antagonism — are not mutually exclusive and likely operate in concert in clinical practice.

From a clinical standpoint, the practical implication is that LDN functions as an endorphin regulator as much as it functions as an immune modulator. If a patient already presents with significant endorphin depletion — a state increasingly prevalent in the post-COVID era due to chronic stress, disrupted sleep, and systemic inflammation — an LDN dose that produces excessive or prolonged receptor blockade will worsen rather than restore endorphin tone. The result is paradoxical: depression, emotional blunting, fatigue, and anhedonia in the very patients for whom mood and energy restoration is the therapeutic goal.

Metz MJ, Daimon CM, Hentges ST. Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and beta-Endorphin. eNeuro. 2021;8(3). PMID: 34031099.

Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663-72. PMID: 19453963.

Post-COVID Physiology and the Changing Patient Landscape

The COVID-19 pandemic introduced a cohort of patients whose neuroimmune and mitochondrial physiology differs, in measurable ways, from the pre-2020 baseline. Long COVID — post-acute sequelae of SARS-CoV-2 infection (PASC) — is estimated to affect approximately 11% of survivors in the United States and upward of 43% globally among those with persistent symptoms. This expanding population has substantially increased the proportion of patients presenting with the phenotype most vulnerable to LDN overdosing.

Three physiological features characterize many post-COVID patients in ways directly relevant to LDN prescribing. First, endorphin depletion: the combination of sustained illness, disrupted sleep, social isolation, and chronic stress has depleted endogenous opioid reserves across a broad swath of the patient population. Patients who may have tolerated 1.5 mg a decade ago may now react adversely to even 0.5 mg. Second, heightened mast cell reactivity: MCAS has emerged as a recognized sequela of SARS-CoV-2 infection, contributing to multisystem hypersensitivity, medication intolerance, and a dramatically reduced threshold for paradoxical reactions. Third, mitochondrial dysfunction: persistent viral interference with mitochondrial electron transport complexes, combined with oxidative stress and dysregulated autophagy, has left many post-COVID patients with profoundly limited metabolic reserve.

A retrospective review of 59 long COVID patients receiving LDN at a single academic medical center found that individualized dose titration ranging from 0.5 mg to 6.0 mg daily was necessary for meaningful clinical benefit, with a substantial minority requiring downward dose adjustments due to adverse effects including worsening fatigue and insomnia. A separate pilot study of LDN combined with NAD+ supplementation in 36 patients with persistent COVID fatigue demonstrated significant quality-of-life improvements at 12 weeks, with insomnia managed in several participants by switching to morning dosing. The era of standardized LDN titration schedules has been superseded by the imperative of individualization.

Tharakan S, Bhalla S, Bhatt D, et al. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. Int Immunopharmacol. 2023. doi:10.1016/j.intimp.2023.111095.

Isman A, Nyquist A, Strecker B, et al. Low-dose naltrexone and NAD+ for treatment of patients with persistent fatigue symptoms after COVID-19. Brain Behav Immun Health. 2024;36:100733. PMID: 38352659.

Bosma-den Boer MM, et al. Low-dose naltrexone for post-COVID fatigue syndrome: study protocol for a double-blind randomised trial. BMJ Open. 2024;14:e085272. PMC11097836.

Paradoxical Reactions: Dose-Overshoot Signals

Among the most clinically consequential insights in LDN practice is the recognition that paradoxical adverse reactions — insomnia where sedation was expected, fatigue where energy was anticipated, depression where mood improvement was the goal — are not idiosyncratic side effects in the traditional pharmacological sense. They are dose-overshoot signals. They communicate that the prescribed dose has exceeded the patient's neuroimmune tolerance threshold and is producing endorphin suppression rather than endorphin restoration.

Clinical series consistently identify insomnia, vivid dreams, low mood, emotional flattening, gastrointestinal disturbance, and increased fatigue as the most frequently reported adverse effects of LDN. These responses are most common during initiation and titration, and their occurrence reliably resolves with dose reduction rather than continuation. A systematic review examining LDN in fibromyalgia confirmed transient insomnia and vivid dreaming as the primary adverse effects, mitigable by dose reduction or morning dosing schedule adjustment. Emotional and mood changes, including unexpected sadness or emotional blunting, have been reported in patients with MCAS and Long COVID even at doses as low as 0.5 to 1.0 mg, underscoring the importance of dose sensitivity awareness.

The practical clinical teaching is unambiguous: when a patient reports any of these symptoms after initiating or increasing LDN, the appropriate response is dose reduction, not a period of watchful waiting. In patients with Long COVID, MCAS, or marked central sensitization, a dose that exceeds biological tolerance by even a modest margin can precipitate a prolonged worsening that sets back the therapeutic relationship considerably. The concept of ultra-sensitive patients who can only tolerate microgram or nanogram quantities is no longer theoretical — it reflects an increasingly common clinical reality.

Afari N, et al. Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review. J Clin Rheumatol. 2023. PMC10039621.

Patten DK, Schultz BG, Berlau DJ. Safety and Efficacy of Low-Dose Naltrexone in Chronic Pain and Inflammation. Pharmacotherapy. 2018;38(3):382-389. PMID: 29377216.

Sleep as a Clinical Biomarker of Therapeutic Adequacy

Sleep architecture offers one of the most accessible and responsive clinical readouts for LDN dosing adequacy. When LDN is correctly dosed and timed — typically administered in the late evening — patients frequently report enhanced dream recall, more vivid and narratively coherent dreaming, and a subjective sense of more restorative sleep. These experiences reflect improvements in REM sleep density mediated by the endorphin surge occurring during the early morning hours when REM sleep predominates. This makes the quality and character of sleep one of the earliest indicators that LDN is reaching therapeutic effect within the correct dose range.

Conversely, insomnia — difficulty initiating or maintaining sleep, early morning awakening, or unrefreshing sleep — is the most commonly reported initial adverse effect of LDN and is almost invariably a dose or timing problem rather than a fundamental incompatibility between patient and medication. When nighttime dosing produces insomnia, a shift to morning administration typically resolves the sleep disruption without sacrificing daytime symptomatic benefit. Clinical evidence confirms that morning dosing is frequently equivalent in efficacy to nocturnal dosing for pain, fatigue, and immune modulation, even if the theoretical rationale favors evening administration. The supervised flexibility to adjust dosing timing is a clinical skill, not a pharmacological compromise.

Monitoring sleep quality and character therefore serves as one of the earliest and most reliable clinical indicators of correct dose calibration. A patient who reports improved sleep architecture within the first two to four weeks of LDN initiation is almost certainly within therapeutic range. A patient who reports worsening insomnia or unrefreshing sleep has almost certainly exceeded it. This real-time feedback loop between sleep quality and dosing adequacy is a practical tool that every LDN-prescribing clinician should actively employ.

Isman A, et al. Brain Behav Immun Health. 2024;36:100733. PMID: 38352659.

Afari N, et al. J Clin Rheumatol. 2023. PMC10039621.

Part II: Methylene Blue — Mitochondrial Reset and Neurotransmitter Amplification

From Industrial Dye to Clinical Pharmacology

Methylene blue (methylthioninium chloride) is among the oldest synthetic pharmaceutical compounds in clinical use, having served successively as a laboratory histological stain, an antimalarial agent, a treatment for methemoglobinemia and ifosfamide-induced encephalopathy, and an intraoperative marker dye for parathyroid and sentinel lymph node localization. Despite this long history, the mechanistic depth that makes MB relevant to contemporary complex chronic illness has only been comprehensively characterized within the past two decades.

MB is an oxidation-reduction (redox) agent existing in dynamic equilibrium between its oxidized (blue) and reduced (leucomethylene blue, colorless) forms. This redox cycling confers its pharmacological utility and distinguishes it fundamentally from passive supplements. MB is a pharmacologically active compound with dose-dependent, pleotropic effects on mitochondrial function, neurotransmitter metabolism, and microbial physiology. Understanding it as merely a supplement dramatically underestimates both its clinical significance and its potential for harm. The staining of urine, saliva, and skin is an expected pharmacological consequence and should be communicated proactively to patients.

Mitochondrial Action: Alternative Electron Transport

The primary therapeutic rationale for MB in conditions involving mitochondrial dysfunction is its capacity to function as an alternative electron carrier within the mitochondrial electron transport chain (ETC). Under normal physiological conditions, electrons flow sequentially from NADH through Complex I, Complex III, and Complex IV, driving the proton gradient that powers ATP synthase (Complex V). When ETC complexes are damaged — as occurs in post-viral syndromes, neurodegeneration, traumatic brain injury, and oxidative injury — electrons may leak from Complex I or Complex III, generating reactive oxygen species (ROS) rather than being productively channeled toward ATP synthesis. This electron leakage initiates a self-sustaining cycle of mitochondrial damage, ROS production, neuroinflammation, and cellular energy depletion.

MB intercepts this pathological cycle by accepting electrons from NADH and donating them directly to cytochrome c between Complexes III and IV, effectively bypassing damaged upstream segments of the ETC and restoring electron flux toward Complex IV. This alternative routing simultaneously increases Complex IV activity, enhances mitochondrial respiration, reduces upstream ROS production, and supports net ATP synthesis. Studies have demonstrated that MB can increase ATP output by 30 to 40% in experimental models, while simultaneously activating Nrf2/ARE antioxidant response element signaling — a self-reinforcing protective cascade against oxidative damage. MB has also been shown to support neurogenesis by ameliorating neuroinflammation and promoting neurite outgrowth and synaptogenesis.

For the clinician treating Long COVID, ME/CFS, or fibromyalgia, this mechanism positions MB as a mitochondrial reset switch: a compound capable of restoring cellular energy production through a parallel pathway when the primary pathway is compromised. This distinguishes it mechanistically from conventional antioxidants, which scavenge ROS after they have formed, and from energy substrates such as CoQ10 or NAD+, which support existing ETC function rather than bypassing damaged segments. In this pharmacological sense, MB functions more similarly to high-dose intravenous vitamin C as a broad-spectrum redox agent with non-selective but powerful biological effects — and, like IV ascorbate, should be respected accordingly.

Rojas JC, Bruchey AK, Gonzalez-Lima F. From Mitochondrial Function to Neuroprotection — an Emerging Role for Methylene Blue. Neurotherapeutics. 2017;14(4):955-974. PMID: 28840449. PMC5826781.

Bhatt S, et al. Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation. Transl Neurodegener. 2020;9(1):19. PMID: 32475349. PMC7262767.

Neurotransmitter Effects: Serotonin Amplification and a Critical Safety Warning

MB exerts significant effects on neurotransmitter metabolism through its well-established inhibition of monoamine oxidase A (MAO-A). MAO-A is the primary enzyme responsible for the intraneuronal degradation of serotonin, norepinephrine, and melatonin. By potently inhibiting MAO-A — with a Ki of approximately 27 nM in human enzyme studies — MB elevates synaptic concentrations of these monoamines, producing effects on mood, cognition, and sleep architecture that may explain some of its observed clinical benefits in conditions associated with neurotransmitter depletion.

The serotonin-amplifying effect of MB has direct relevance to sleep architecture. Serotonin serves as a biosynthetic precursor to melatonin: adequate synaptosomal serotonin availability is a prerequisite for effective melatonin synthesis in the pineal gland. Patients who fail melatonin supplementation — a common observation in those with chronic illness — may be failing not because exogenous melatonin is inherently ineffective, but because insufficient upstream serotonin is available to prime the serotonin-to-melatonin conversion pathway. MB's MAO-A inhibition may, in principle, restore this upstream serotonin availability, enabling melatonin to function where it previously could not. This mechanism is biologically plausible and consistent with observed clinical responses, though prospective human studies confirming this specific pathway remain limited.

Any patient receiving an SSRI, SNRI, or other serotonergic agent should not receive methylene blue without careful risk stratification and specialist guidance. This is a documented, potentially fatal pharmacological interaction — not a theoretical concern.

The MAO-A inhibitory mechanism of MB carries a critical, potentially life-threatening contraindication that every prescribing clinician must understand without exception. Serotonin syndrome — a potentially fatal condition characterized by hyperthermia, agitation, tremor, myoclonus, hyperreflexia, and autonomic instability — can occur when a potent MAO-A inhibitor is administered concurrently with a serotonin reuptake inhibitor. The FDA has issued a formal Drug Safety Communication addressing this interaction, following multiple case reports of serotonin toxicity occurring when MB was administered to surgical patients maintained on SSRIs or SNRIs. While the majority of documented cases involved intravenous MB at doses of 1 to 8 mg/kg in the perioperative setting, the fundamental pharmacodynamic risk is inherent to the molecule's MAO-A inhibitory properties regardless of route of administration. It should be treated as a class-level warning applicable to any clinical use of MB.

Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol. 2007;150(6):757-760. PMID: 17721552. PMC2078225.

FDA Drug Safety Communication. Updated information about the drug interaction between methylene blue (methylthioninium chloride) and serotonergic psychiatric medications. U.S. FDA. 2016.

Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of MAO A confirms a theoretical prediction. Br J Pharmacol. 2007. PMID: 17721552.

Antimicrobial and Terrain-Resetting Properties

At higher concentrations, MB exhibits broad-spectrum antimicrobial activity, consistent with its original use as an antimalarial agent in the early twentieth century. This activity reflects its capacity to generate reactive oxygen species in a targeted, photochemically enhanced manner within microbial cells. While the therapeutic use of MB for its antimicrobial properties in the context of chronic tick-borne illness or biofilm-associated infections remains largely anecdotal and investigational, the underlying redox mechanism is biologically plausible and consistent with in vitro evidence. Some clinicians have conceptualized higher-dose MB as part of a broader 'terrain reset' strategy in patients with suspected chronic occult infections — an approach that shares conceptual ground with high-dose intravenous ascorbate protocols and should similarly be approached with appropriate clinical oversight.

Part III: The Clinical Logic of LDN and Methylene Blue in Combination

Addressing Both the Software and Hardware of Chronic Illness

Complex chronic illnesses — Long COVID, fibromyalgia, ME/CFS, MCAS, and their overlapping phenotypes — involve dysfunction at two interconnected levels. At the signaling level, dysregulated neuroimmune communication drives chronic neuroinflammation, centralized pain sensitization, and immune dysregulation. At the energetic level, mitochondrial dysfunction reduces cellular ATP availability, impairs mitophagy and cellular quality control, and sustains the oxidative stress that perpetuates both neuroinflammation and immune activation. A therapeutic strategy that addresses only one of these levels will produce incomplete and often unstable clinical benefit.

LDN operates primarily at the signaling level: it modulates neuroimmune communication through TLR4 antagonism on microglia, restores endorphin tone through transient opioid receptor blockade, and dampens the neuroinflammatory cascade underlying many cognitive, pain, and mood symptoms in chronic illness. MB operates primarily at the energetic level: it restores electron flux in damaged mitochondrial ETC, increases ATP synthesis, reduces ROS production, and supports neurotransmitter biosynthesis through MAO-A inhibition. Their mechanisms are genuinely complementary rather than redundant — they do not compete for the same pathways but reinforce each other through distinct biological domains.

In combination, LDN addresses the 'software' of chronic illness — the dysregulated signaling networks governing neuroimmune communication — while MB addresses the 'hardware' — the cellular energy generation infrastructure upon which all signaling depends. Neither agent alone is sufficient for many of the most severely affected patients. Together, they create the biological conditions necessary for meaningful, durable recovery: a calmed neuroimmune system operating on restored cellular energy. This mechanistic complementarity constitutes the conceptual foundation for their combination use in integrative clinical practice.

Practical Considerations: Dosing, Compounding, and Patient-Centered Adaptation

The practical implementation of LDN and MB therapy requires attention to compounding access, formulation quality, patient education, and cost management. LDN is not commercially available in therapeutic doses below 50 mg; it must be compounded by a licensed pharmacy, which introduces variability in formulation quality and geographic access. Oral liquid formulations are particularly valuable for patients requiring ultra-low dosing in the microgram range, as capsule formulations at these quantities are technically difficult to prepare with consistency. Practitioners should develop relationships with compounding pharmacies experienced in LDN preparation and should verify quality assurance practices.

MB is commercially available in pharmaceutical-grade oral solutions and other formulations. Expected effects including blue-green discoloration of urine, saliva, and occasionally skin should be communicated proactively. The timeline of clinical response differs between the two agents: MB's effects on energy, mood, and cognition may become apparent within days to weeks, while LDN typically requires four to twelve weeks of consistent use before meaningful clinical effect is established. Setting accurate expectations regarding timeline, therapeutic indicators, and the importance of dose monitoring is essential to patient retention and therapeutic success.

Access barriers remain a significant real-world challenge. Compounding pharmacies vary substantially in cost and quality. In clinical settings where standard pharmacy access is limited, some practitioners have employed supervised dilution protocols to achieve microgram-range dosing from available preparations — a practice that requires careful patient instruction, appropriate measuring equipment, and close clinical oversight. The integrative clinician's obligation is to adapt within the boundaries of safety and professional responsibility, recognizing that clinical reality often requires solutions that extend beyond textbook medicine without departing from its foundational principles.

Toljan K, Vrooman B. Low-Dose Naltrexone (LDN) — Review of Therapeutic Utilization. Med Sci. 2018;6(4):82. PMC6313374.

Selected References

1. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-9. PMID: 24526250. PMC3962576.

2. Poliwoda S, Noss B, Truong GTD, et al. The Utilization of Low Dose Naltrexone for Chronic Pain. CNS Drugs. 2023;37(8):663-670. PMID: 37505425.

3. Patten DK, Schultz BG, Berlau DJ. The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders. Pharmacotherapy. 2018;38(3):382-389. PMID: 29377216.

4. Metz MJ, Daimon CM, Hentges ST. Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and beta-Endorphin. eNeuro. 2021;8(3):ENEURO.0087-21.2021. PMID: 34031099.

5. Tharakan S, Bhalla S, Bhatt D, et al. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19 (PASC). Int Immunopharmacol. 2023. doi:10.1016/j.intimp.2023.111095.

6. Isman A, Nyquist A, Strecker B, et al. Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19. Brain Behav Immun Health. 2024;36:100733. PMID: 38352659. PMC10862402.

7. Bosma-den Boer MM, et al. Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia. BMJ Open. 2024;14(5):e085272. PMID: 38740493. PMC11097836.

8. Vatvani AD, et al. Low-Dose Naltrexone for Severe Fibromyalgia Syndrome: A Report of a Case With Two-Year Follow-Up. Cureus. 2025. PMC12146906.

9. Afari N, et al. Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review. J Clin Rheumatol. 2023. PMC10039621.

10. Kim PS, Fishman MA. Low-Dose Naltrexone for Chronic Pain: Update and Systematic Review. Curr Pain Headache Rep. 2020;24(10):64. PMID: 32845365.

11. Rojas JC, Bruchey AK, Gonzalez-Lima F. From Mitochondrial Function to Neuroprotection — an Emerging Role for Methylene Blue. Neurotherapeutics. 2017;14(4):955-974. PMID: 28840449. PMC5826781.

12. Bhatt S, et al. Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation. Transl Neurodegener. 2020;9(1):19. PMID: 32475349. PMC7262767.

13. Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol. 2007;150(6):757-760. PMID: 17721552. PMC2078225.

14. FDA Drug Safety Communication. Updated information about the drug interaction between methylene blue (methylthioninium chloride) and serotonergic psychiatric medications. U.S. Food and Drug Administration. 2016.

15. Toljan K, Vrooman B. Low-Dose Naltrexone (LDN) — Review of Therapeutic Utilization. Med Sci (Basel). 2018;6(4):82. PMID: 30347787. PMC6313374.

16. Yang SH, Li W, Sumien N, et al. Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots. Prog Neurobiol. 2017;159:60-82. PMID: 27090289.

17. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663-72. PMID: 19453963.

© 2026 Direct Integrative Care  |  www.directintegrativecare.com  |  For educational purposes only. Not for distribution without clinical context.